Survodutide vs Brenipatide
A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver. A once-monthly dual GIP/GLP-1 agonist aimed at the brain's reward circuitry rather than the scale. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Survodutide BI 456906 | Brenipatide LY3537031 | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Analog |
| Evidence | Investigational | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Glucagon/GLP-1 dual receptor agonist (acylated peptide) | GIP/GLP-1 dual agonist (acylated peptide) |
| Receptor / target | Glucagon receptor (GCGR) + GLP-1 receptor | GIP + GLP-1 receptors |
| Molecular weight | ≈4,800 Da | ≈4,900 Da |
| Half-life | engineered for once-weekly dosing | engineered for once-monthly dosing |
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Survodutide and Brenipatide?
- Survodutide is an engineered analog based on Glucagon-like peptide-1; Brenipatide is an engineered analog based on Glucagon-like peptide-1. Survodutide signals at Glucagon receptor (GCGR) + GLP-1 receptor; Brenipatide signals at GIP + GLP-1 receptors.
- How do the half-lives of BI 456906 and LY3537031 compare?
- The reported circulating half-life of Survodutide is engineered for once-weekly dosing; Brenipatide is engineered for once-monthly dosing. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Brenipatide vs Survodutide. Or open the interactive comparison tool to add more molecules.